

| Catalog No. | HB651226 |
|---|---|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Human |
| Isotype | IgG |
| Clone ID | JMW-3B3 |
| Biological activity | Biotinylated JMW-3B3 (10 ug/mL) specifically detects sCTLA-4 in PBMC cell culture supernatants, and reveals no population-level difference in sCTLA-4 production between SLE patient and healthy donor PBMC stimulated with lupus-associated autoantigenic peptides [1]. JMW-3B3 (10 ug/mL; 5 days) blocks sCTLA-4 activity in PBMC from both healthy donors and SLE patients, with effects that vary by stimulant: it suppresses some pro-inflammatory and proliferative responses in healthy donors, while enhancing IL-10 production (and altering proliferation/cytokine profiles) in SLE patient PBMC, accentuating the inherent cytokine response differences between the two groups [1]. JMW-3B3 (20 ug/mL; overnight at 4°C) selectively binds intracellular sCTLA-4 in G-361 human malignant melanoma epithelial cells, but does not detect sCTLA-4 in A-375 human malignant melanoma epithelial cells [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IFN-γ production from melanoma patient PBMC stimulated with a low dose (0.02 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2]. JMW-3B3 (10 ug/mL; 5 days) enhances IL-17A production from healthy donor PBMC stimulated with a high dose (1 ug/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment [2]. |
| Expression system | Mammalian cells |
| Clonality | Monoclonal |
| Target | CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4 |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P16410 |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | JMW-3B3, JMW3B3, JMW3B3 |
| Background | Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy). 1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501 2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244 4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933 5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304 6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017 |
| References | 1. Dahal LN, et al. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. Arthritis Res Ther. 2016;18:180. Published 2016 Aug 4. [HB651226] 2. Khanolkar RC, et al. TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. Front Immunol. 2022;12:763877. Published 2022 Jan 5. [HB651226] |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD152/CTLA4 (JMW-3B3)




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com


+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский